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Summary
Background Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an effective and 
deployable vaccine. RTS,S/AS01, the most effective malaria vaccine candidate to date, demonstrated 56% efficacy over 
12 months in African children. We therefore assessed a new candidate vaccine for safety and efficacy.
Methods In this double-blind, randomised, controlled, phase 2b trial, the low-dose circumsporozoite protein-based 
vaccine R21, with two different doses of adjuvant Matrix-M (MM), was given to children aged 5–17 months in Nanoro, 
Burkina Faso—a highly seasonal malaria transmission setting. Three vaccinations were administered at 4-week intervals 
before the malaria season, with a fourth dose 1 year later. All vaccines were administered intramuscularly into the thigh. 
Group 1 received 5 µg R21 plus 25 µg MM, group 2 received 5 µg R21 plus 50 µg MM, and group 3, the control group, 
received rabies vaccinations. Children were randomly assigned (1:1:1) to groups 1–3. An independent statistician 
generated a random allocation list, using block randomisation with variable block sizes, which was used to assign 
participants. Participants, their families, and the local study team were all masked to group allocation. Only the 
pharmacists preparing the vaccine were unmasked to group allocation. Vaccine safety, immunogenicity, and efficacy were 
evaluated over 1 year. The primary objective assessed protective efficacy of R21 plus MM (R21/MM) from 14 days after the 
third vaccination to 6 months. Primary analyses of vaccine efficacy were based on a modified intention-to-treat population, 
which included all participants who received three vaccinations, allowing for inclusion of participants who received the 
wrong vaccine at any timepoint. This trial is registered with ClinicalTrials.gov, NCT03896724.
Findings From May 7 to June 13, 2019, 498 children aged 5–17 months were screened, and 48 were excluded. 
450 children were enrolled and received at least one vaccination. 150 children were allocated to group 1, 150 children 
were allocated to group 2, and 150 children were allocated to group 3. The final vaccination of the primary series was 
administered on Aug 7, 2019. R21/MM had a favourable safety profile and was well tolerated. The majority of adverse 
events were mild, with the most common event being fever. None of the seven serious adverse events were attributed 
to the vaccine. At the 6-month primary efficacy analysis, 43 (29%) of 146 participants in group 1, 38 (26%) of 
146 participants in group 2, and 105 (71%) of 147 participants in group 3 developed clinical malaria. Vaccine efficacy 
was 74% (95% CI 63–82) in group 1 and 77% (67–84) in group 2 at 6 months. At 1 year, vaccine efficacy remained 
high, at 77% (67–84) in group 1. Participants vaccinated with R21/MM showed high titres of malaria-specific anti-
Asn-Ala-Asn-Pro (NANP) antibodies 28 days after the third vaccination, which were almost doubled with the higher 
adjuvant dose. Titres waned but were boosted to levels similar to peak titres after the primary series of vaccinations 
after a fourth dose administered 1 year later.
Interpretation R21/MM appears safe and very immunogenic in African children, and shows promising high-level 
efficacy.
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Introduction
Malaria remains one of the leading causes of morbidity 
and mortality worldwide. Plasmodium falciparum is a 
complex pathogen with numerous immune evasion 
mechanisms. Development of an efficacious vaccine 
against this parasite has remained elusive for many 
decades. The leading malaria vaccine candidate, 
RTS,S/AS01, induces partial efficacy through induction 
of antibodies against the central repeat (Asn-Ala-Asn-Pro 
[NANP]) of the circumsporozoite protein (CSP).1 Efficacy 
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was assessed in a phase 3 study of 15 460 children and 
infants living in seven sub-Saharan African countries 
between 2009 and 2013.2,3 Overall vaccine efficacy for 
children aged 5–17 months, with a median follow-up 
of 48 months, was 36% for children administered 
RTS,S/AS01 at months 0, 1, 2, and 20, and 28% for 
children given the vaccine at months 0, 1, and 2. For 
infants aged 6–12 weeks, efficacy was 26% for children 
given the vaccine at months 0, 1, 2, and 20, and 18% for 
children given the vaccine at months 0, 1, and 2.2 These 
studies showed modest efficacy, leading to a positive 
scientific opinion by the European Medicines Agency; 
however, possible safety signals of increased incidence 
of meningitis, cerebral malaria cases,2,4,5 and increased 
female mortality in malaria vaccine groups were also 
observed.6,7 The question of feasibility of a four-dose 
schedule requiring new contacts also arose. Therefore, 
RTS,S/AS01 has not yet been prequalified for use by 
WHO, but instead a malaria vaccine imple mentation 
programme was launched in three countries over the 
course of 2019.8
There remains an urgent need to identify and develop 
improved vaccine candidates that could achieve the 
WHO goal of 75% efficacy against clinical malaria 
by 2030.9 R21 is a novel pre-erythrocytic candidate malaria 
vaccine. R21 and RTS,S both include HBsAg fused to the 
C-terminus and central repeats of the CSP, which self-
assemble into virus-like particles in yeast. R21 lacks 
the excess HBsAg found in RTS,S. R21 comprises only 
fusion protein moieties, in contrast to RTS,S, which 
comprises 20% with the remaining 80% being HBsAg 
monomers expressed alone, thereby likely diminishing 
CSP coverage of the virus-like particle surface.10,11
Following preclinical studies of R21 plus multiple 
adjuvants, Matrix-M (R21/MM) was selected for clinical 
development based on high immunogenicity.10 It is a 
saponin-based adjuvant that stimulates both humoral 
and cellular immune responses to vaccines.10,12 In 
phase 1/2a clinical trials, R21/MM showed a good safety 
profile and strong antibody responses to the CSP central 
repeat, NANP, using a dose of 5 µg R21. Importantly, 
sterile efficacy rates of 63–78% were observed during 
controlled human malaria infection trials after three doses 
of 10 µg R21/MM, administered intramuscularly 4 weeks 
apart.13,14
Following an age de-escalation trial of R21/MM in 
Kenyan adults, children, and infants,15 which has shown 
a well tolerated safety profile and potent immunogenicity, 
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Research in context
Evidence before this study
There are currently no licensed vaccines to protect against 
Plasmodium falciparum malaria. We searched PubMed from 
database inception to March 23, 2021, for published research 
articles using the terms “malaria vaccine”, “clinical trial”, 
“phase III”, AND “efficacy”. No language restrictions were 
applied. The search identified one published large phase 3 
clinical trial describing a trial of the pre-erythrocytic malaria 
vaccine candidate, RTS,S/AS01 (Mosquirix), done at 11 sites in 
seven countries across sub-Saharan Africa. This vaccine 
candidate has now progressed to pilot implementation trials 
after showing efficacy of 36% after four doses, over a median of 
48 months follow-up. Efficacy of 56% in children aged 
5–17 months was observed over the first year.
Due to the high burden and wide geographical distribution of 
P falciparum, in the most recent update to the Malaria Vaccine 
Technology Roadmap, WHO called for the development of 
malaria vaccine candidates with a protective efficacy of at least 
75% against clinical malaria by 2030, to address this unmet 
priority public health goal.
Added value of this study
This study reports vaccine efficacy of a novel pre-erythrocytic 
candidate malaria vaccine in a phase 2 trial in children living in a 
malaria endemic area with high transmission in Burkina Faso. 
This new vaccine, R21 adjuvanted with 50 µg Matrix-M 
(R21/MM), administered before the malaria season, 
demonstrates high-level efficacy, reaching the WHO-specified 
efficacy goal of at least 75% in the target population of African 
children over 1 year. Furthermore, R21/MM demonstrates a 
favourable safety profile. It is well tolerated with the majority of 
local and systemic adverse events graded mild, and no serious 
adverse events related to vaccination in the trial. Importantly, 
although this vaccine immunogen is similar to RTS,S, it does 
not have the excess HBsAg found in RTS,S and provides a 
higher density of circumsporozoite protein epitopes on the 
particle surface, resulting in high levels of malaria-specific 
anti-Asn-Ala-Asn-Pro (NANP) antibodies. These antibodies 
were effectively boosted 1 year later to levels similar to those 
after the primary series of vaccinations.
This phase 2 trial is currently continuing for a second malaria 
season, after the booster vaccine, to determine whether high 
vaccine efficacy can be maintained.
Implications of all the available evidence
These initial findings with the new R21/MM vaccine candidate 
appear to improve on the efficacy in children of all other malaria 
vaccines. These data support the further evaluation of this 
promising malaria vaccine candidate in a phase 3 trial that will 
embrace different malaria transmission settings, the 
coadministration of seasonal malaria chemoprevention, and 
encompass a wider age range with a high incidence of malaria. 
An important additional advantage of the new R21/MM 
malaria vaccine candidate is its potential for large-scale 
manufacturing and low-cost supply, to support global efforts to 
better control, sustainably eliminate, and finally eradicate 
malaria.
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we initiated a phase 1/2b safety, immunogenicity, and 
efficacy trial of this novel pre-erythrocytic malaria vaccine 
candidate in children aged 5–17 months in Nanoro, 
Burkina Faso. To ensure antibody responses were highest 
during the seasonal peak of malaria transmission, 
resulting in potentially increased vaccine efficacy, we 
administered three doses in the primary vaccination 
series largely before the malaria season.16
Methods
Study design and participants
This was a phase 2b, randomised, controlled, double-
blind trial done at the Institut de Recherche en Sciences 
de la Santé, Nanoro, Burkina Faso. Participants aged 
5–17 months were recruited from the Health and 
Demographic Surveillance System catchment area of 
Nanoro, which covers 24 villages, with an approximate 
population of 65 000 inhabitants. Nanoro is an area of 
high malaria transmission, with transmission occurring 
throughout the year, but with a marked peak during the 
rainy season (June to November).
Eligible participants were recruited into three groups. 
Group 1 received 5 µg R21/25 µg MM, group 2 received 
5 µg R21/50 µg MM, and group 3, the control group, 
received rabies vaccinations. Doses were administered 
before the seasonal peak of malaria transmission starting 
in July. Safety, immunogenicity, and vaccine efficacy are 
being assessed over 24 months, with the primary efficacy 
endpoint after 6 months, after the primary series of 
vaccinations (three doses). All participants also received a 
booster vaccination approximately 12 months after their 
third vaccination, before the start of the next malaria 
season. Field workers collected data on indoor residual 
spraying of households, insecticide treated net use (and if 
the nets were adequate, according to if holes were present), 
number of doses of seasonal malaria chemoprevention 
taken by the participant per month, and number of 
months seasonal malaria chemoprevention was taken 
during the malaria season.
After community sensitisation, a list of eligible 
children was drawn from the Health and Demographic 
Surveillance System database, and parents or legally 
authorised guardians who expressed interest were 
invited to screening visits. During recruitment, parents 
or legally authorised guardians of participants provided 
written or thumb-printed consent, which was verbally 
checked at each study visit. Inclusion criteria specified 
that participants should be aged 5–17 months at 
enrolment, parents should provide written informed 
consent, and aim to be living in the study area for the 
trial duration. Exclusion criteria included significant 
comorbidities and participation in other malaria inter-
vention studies and clinical trials. Further details are 
given in the protocol (appendix pp 13–91).
The trial was approved by the Comité d’Ethique 
pour la Recherche en Santé, Burkina Faso (reference 
number 2019-01-012), and the national regulatory 
authority, Agence National de Régulation Pharmaceutique, 
Burkina Faso (reference number 5005420193EC0000). 
Ethical approval was also granted in the UK by the 
Oxford Tropical Research Ethics Committee (reference 
number 19-19).
Randomisation and masking
Children aged 5–17 months were randomly assigned (1:1:1) 
to groups 1–3. An independent statistician generated a 
random allocation list, using block randomisation with 
variable block sizes. A person independent of the trial 
prepared and sealed the envelopes using this list, which 
was then given to the pharmacist to assign to participants. 
Both malaria and control vaccines were prepared by 
the pharmacist using the same type of syringe, and the 
contents of the syringe were covered with an opaque 
label. The trial was double-blinded; participants, their 
families, and the local study team were all masked to 
group allocation. Only the pharmacists preparing the 
vaccine were unmasked to group allocation.
Procedures
R21 was produced by expressing recombinant HBsAg 
virus-like particles in Hansenula polymorpha, comprising 
the central repeat and the C-terminus of the CSP fused to 
the N-terminal end of HBsAg10 and manufactured by the 
Serum Institute of India (Pune, India). R21 was mixed 
immediately before administration with MM, a saponin-
based vaccine adjuvant produced by Novavax (Uppsala, 
Sweden). A rabies vaccine (Rabivax-S), manufactured by 
the Serum Institute of India, was the control vaccine. 
All vaccines were administered intramuscularly into the 
thigh.
On the day of vaccination, participants were tested for 
malaria if they had a fever of 37·5°C or higher. If their 
blood film was positive for Plasmodium spp, they were 
treated for malaria in accordance with national guidelines 
before having a vaccination.
After each vaccination, local and systemic solicited 
adverse events were collected for 7 days. Intensity 
of symptoms was evaluated following standardised 
methods. Unsolicited adverse events were collected for 
28 days after vaccinations, and safety laboratory values 
were measured at 28 days after the first and third 
vaccinations to look for deviations from baseline. Serious 
adverse events are being recorded for the duration of the 
study. Clinical judgment by study clinicians was used 
to assess causality of adverse events and relationship 
to vaccine. All adverse events were followed up until 
resolution.
Data safety monitoring board reviews were held after 
the vaccination of the first 30 participants, and after 
completion of the primary series of three vaccinations.
Parents of participants were advised to attend the 
community health facility if their child had any illness, 
or a temperature of 37·5°C or higher or history of fever 
within the last 24 h, or both, for review and assessment 
See Online for appendix
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for malaria. After the third vaccination, participants 
were visited by field workers every 30 days until 
6 months after the third vaccination, when, if they had 
a temperature of 37·5°C or higher or history of fever 
within the last 24 h, or both, blood sampling was done 
for blood film microscopy to detect Plasmodium spp. 
Two independent microscopists, who were masked to 
the vaccination status of all participants, analysed each 
blood film, with a third microscopist adjudicating in 
cases of discrepancy.
Anti-NANP antibodies were measured by ELISA before 
first vaccination, as previously described,17,18 28 days after 
first vaccination; 28 days, 6 months, and 1 year after the 
third vaccination; and 28 days after the booster dose 
administered 1 year later.
Outcomes
The primary objective assessed protective efficacy of 
R21/MM against clinical malaria from 14 days after 
the third vaccination to 6 months. The primary case 
definition of clinical malaria was presence of an axillary 
temperature of 37·5°C or higher and P falciparum 
asexual parasite density of more than 5000 parasites 
per µL. The secondary case definition was presence of 
an axillary temperature of 37·5°C or higher or history of 
fever during the last 24 h, or both, and P falciparum 
parasite density of more than 0 parasites per µL. The 
secondary objective assessed protective efficacy of 
R21/MM from 14 days after the third vaccination to 
12 months. In addition, cross-sectional asymptomatic 
P falciparum infection was analysed at months 6 and 12, 
defined as the presence of axillary temperature of less 
than 37·5°C, absence of history of fever within the last 
24 h, and P falciparum parasite density of more than 
0 parasites per µL. Safety, reactogenicity, and humoral 
immuno genicity of R21/MM were evaluated.
Statistical analysis
The study was powered to provide an initial point 
estimate of the efficacy of the malaria vaccine in either 
group 1 or 2, assuming that the vaccine efficacy over 
6 months was greater than 50%. Due to an unexpectedly 
high participant retention rate, we had power to detect 
efficacy greater than 37%.
Cox regression models were used to analyse first 
episodes of clinical malaria from 14 days after the third 
vaccination to 6 months and 1 year. For participants 
without an episode of clinical malaria, their time was 
censored at the date of their withdrawal or the date of 
their 6-month or 12-month blood sampling. The primary 
comparisons were prespecified as being between 
groups 1 and 3 and groups 2 and 3, with comparison of 
Figure 1: Trial profile
The main reason for withdrawal or not completing vaccination regimen was relocation outside of the study area. The parent of one participant withdrew consent after the first vaccination and 
two participants died during the course of the study, unrelated to vaccination. *All participants who received the third vaccination were analysed for the primary outcome, because participants with no 
event were censored at date of 12-month blood draw or date of withdrawal, except for three participants who withdrew within 14 days of third vaccination.
450 randomly assigned 
498 children screened for eligibility 
48 excluded
 27 not eligible
 21 declined to participate
150 allocated to 5 µg R21/50 µg Matrix-M 
and received allocated vaccine 
139 completed 12-month blood draw  
11 excluded
 8 lost to follow-up or 
withdrew
 3 did not receive all 
vaccines
 
146 analysed at 12 months*
1 withdrew 7 days after third 
vaccine
 
150 allocated to control vaccine and 
received allocated vaccine
142 completed 12-month blood draw
8 excluded
7 lost to follow-up or 
withdrew
1 did not receive all vaccines
 
147 analysed at 12 months* 
2 withdrew 7 days after third 
vaccine
 
150 allocated to 5 µg R21/25 µg Matrix-M 
and received allocated vaccine
134 completed 12-month blood draw 
16 excluded
 12 lost to follow-up or 
withdrew
 4 did not receive all 
vaccines
 
146 analysed at 12 months*
Articles
www.thelancet.com   Vol 397   May 15, 2021 1813
groups 1 and 2 to 3 as a supplementary analysis. A 
secondary analysis adjusted for confounding factors of 
sex, age at randomisation (5–9 months, 10–12 months, or 
>12 months) and bednet use (adequate or not). Vaccine 
efficacy was calculated as 1 minus the hazard ratio (HR).
Primary analyses of vaccine efficacy were based on a 
modified intention-to-treat population, which included all 
participants who received three vaccinations, allowing for 
inclusion of participants who received the wrong vaccine 
at any timepoint. Because all vaccines were administered 
correctly, this is equivalent to a per-protocol analysis.
The secondary outcomes of asymptomatic malaria 
infection at months 6 and 12 were analysed using a log 
binomial model, including randomised group as a 
covariate. Relative risks and 95% CIs were reported for 
comparisons of groups 1 and 3, and groups 2 and 3. This 
analysis was also done with adjustment for the con-
founding factors previously described.
To search for an immunological correlate of protection, 
we divided participants by tertile on their antibody 
response 4 weeks after the third dose and searched for 
differences in risk of clinical malaria.2
To facilitate masking, analyses were done by 
statisticians external to the investigator teams.
All statistical analyses were done using Stata, 
version 16.1.
This study is registered with ClinicalTrials.gov, 
NCT03896724.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
From May 7 to June 13, 2019, 498 children aged 
5–17 months were screened (figure 1). 48 children were 
excluded, leaving 450 children who were enrolled and 
received at least one vaccination. 150 children were 
allocated to 5 µg R21 plus 25 µg MM (group 1), 
150 children were allocated to 5 µg R21 plus 50 µg MM 
(group 2), and 150 children were allocated to the control 
vaccine (group 3). The final vaccination of the primary 
series was administered on Aug 7, 2019. Baseline 
demographic characteristics were similar across the 
groups and the combined mean age of children 
completing vac cinations was 11·6 months (SD 3·8), with 
220 male participants and 222 female participants 
(appendix p 1). Eight of the 450 participants enrolled 
withdrew before the third vaccination and three at 7 days 
after the third vaccination. 383 (87%) of 442 participants 
adequately used insecticide treated nets before the 
malaria season. Indoor residual spraying was done 
in 65 (15%) of 441 households, and 300 (68%) of 
442 participants had at least one round (ie, three 
consecutive doses per day in 1 month; appendix p 2) of 
seasonal malaria chemoprevention.
186 participants had clinical malaria according to the 
primary case definition when assessing the primary 
objective of efficacy against clinical malaria of R21/MM 
from 14 days after the third vaccination to 6 months. 
These cases of clinical malaria occurred in 43 (29%) of 
146 participants in group 1, 38 (26%) of 146 participants 
in group 2, and 105 (71%) of 147 participants in group 3. 
A Cox regression model comparing group 1 with 
group 3 resulted in vaccine efficacy of 74% (95% CI 
63–82; p<0·0001). Comparing group 2 with group 3 
resulted in 77% efficacy (67–84; p<0·0001; figure 2).
Efficacy was further assessed at 12 months 
(range 329–369 days) after the third vaccination. 
Figure 2: Kaplan-Meier estimates of the time to first episode of clinical malaria
The primary analysis was based on a modified intention-to-treat population. Group 1 received 5 µg R21/25 µg MM, 
group 2 received 5 µg R21/50 µg MM, and group 3, the control group, received rabies vaccinations (Rabivax-S). 
(A) Data beginning from 14 days to 6 months after third vaccination. (B) Data beginning from 14 days to 
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195 participants had clinical malaria—an increase of 
nine participants from the primary 6-month analysis 
(the period of low malaria transmission). These cases 
occurred in 50 (34%) of 146 participants in group 1, 
39 (27%) of 146 participants in group 2, and 106 (72%) of 
147 participants in group 3. Cox regression showed 
vaccine efficacy of 71% (95% CI 59–79; p<0·0001) for 
group 1, and 77% (67–84; p<0·0001) for group 2 (figure 2). 
No significant difference in disease incidence was found 
between groups 1 and 2 at either 6 months or 12 months. 
Calculation of the numbers of cases that would be 
averted19 by the vaccination regimens, based on numbers 
of all malaria episodes and case incidence rates over 
12 months (appendix p 2), indicated a rate reduction of 
1393 cases (95% CI 1043–1744) per 1000 children-years 
in group 1, and 1523 cases (1172–1875) per 1000 children-
years in group 2 (appendix p 2).
224 participants had a first episode of clinical malaria 
by 12 months according to the secondary case definition, 
including clinical cases with parasitaemia of more than 
0 parasites per µL. A Cox regression model comparing 
group 1 with group 3 showed vaccine efficacy of 70% 
(95% CI 60–78; p<0·0001), and 80% (72–86; p<0·0001) 
when comparing group 2 with group 3 (table 1).
Secondary analyses of vaccine efficacy, according to the 
primary case definition, were done between 14 days after 
the third vaccination and 6 months or 12 months, 
adjusting for potentially confounding factors of sex, age 
at randomisation, and adequate bednet use. Using a Cox 
regression model, comparing group 1 with group 3 
showed a vaccine efficacy of 75% (95% CI 67–81; 
p<0·0001) and comparing group 2 with group 3 showed 
a vaccine efficacy of 77% (65–80; p<0·0001) at 12 months 
(table 1). Further adjustment for use of seasonal malaria 
chemoprevention showed no change to the vaccine 
efficacy estimates.
Cross-sectional blood films were done after 6 months 
and 12 months of follow-up. At 6 months, 28 (19%) of 
147 participants in group 3 had asymptomatic parasit-
aemia, with fewer participants in groups 1 (12 [9%] of 140; 
p=0·01), and 2 (13 [9%] of 145; p=0·01) with asymptomatic 
parasitaemia. At 12 months, this number was reduced 
to six (4%) of 142 participants in group 3, three (2%) of 
132 participants (p=0·37) in group 1; and two (1%) of 
141 participants (p=0·18) in group 2 (appendix p 4).
Seven serious adverse events were reported in 
participants (appendix p 3) and all were deemed unrelated 
to vaccination. One serious adverse event was a partici-
pant who presented 17 days after their first R21/MM 
vaccination with fever, a convulsion, and generally unwell. 
They were severely anaemic with a blood film positive for 
P falciparum. They were diagnosed and treated for severe 
malaria, and transferred to the referral hospital but died 
shortly thereafter.
Local adverse events of redness, swelling, and pain 
were reported in a small proportion of participants. 
25 (2%) episodes of pain were noted after 1159 R21/MM 
vaccinations (table 2; appendix pp 5–6). Fever, loss of 
appetite, irritability, and drowsiness were the systemic 
adverse events collected for 7 days after each vaccination. 
Fever was the most common adverse event for all groups, 
occurring in 14 (9%) of 150 participants in group 1, 
28 (19%) of 150 participants in group 2, and 13 (9%) of 
150 participants in group 3 after the first vaccination. 
Fever occurred in 18 (12%) of 149 participants in group 1, 
44 (30%) of 147 participants in group 2, and seven (5%) of 
149 participants in group 3 after the second vaccination; 
and in 18 (12%) of 146 participants in group 1, 29 (20%) of 
147 participants in group 2, and 16 (11%) of 149 participants 
in group 3 after the third vaccination (table 2; appendix 
p 5). After the booster dose, rates of fever were similar, 
occurring in 19 (14%) of 132 participants in group 1, 
34 (25%) of 138 participants in group 2, and eight (6%) of 
140 participants in group 3 (table 2; appendix p 6). Only 
two participants had grade 3 fever (>39·0°C), and these 
events were after the third vaccination in groups 1 and 2. 
Overall, there were significantly more fevers in group 2 
(odds ratio 2·214 [95% CI 1·614–3·026]; p<0·0001) than 
Timepoint 
(months)
Number with at least 







Primary (>5000 parasites per µL) 6 43/146 (30%) 74% (63–82) 74% (63–82)
Primary (>5000 parasites per µL) 12 50/146 (34%) 71% (59–79) 71% (59–79)
Secondary (>0 parasites per µL) 6 53/146 (36%) 73% (63–81) 74% (64–81)
Secondary (>0 parasites per µL) 12 61/145 (42%) 70% (60–78) 71% (60–79)
Group 2
Primary (>5000 parasites per µL) 6 38/146 (26%) 77% (67–84) 76% (65–84)
Primary (>5000 parasites per µL) 12 39/146 (27%) 77% (67–84) 76% (65–84)
Secondary (>0 parasites per µL) 6 43/146 (30%) 79% (70–85) 78% (69–85)
Secondary (>0 parasites per µL) 12 43/146 (30%) 80% (72–86) 80% (71–86)
Groups 1 and 2 combined
Primary (>5000 parasites per µL) 6 81/292 (28%) 76% (67–82) 75% (67–82)
Primary (>5000 parasites per µL) 12 89/292 (31%) 74% (65–80) 73% (65–80)
Secondary (>0 parasites per µL) 6 96/292 (33%) 76% (69–82) 76% (69–82)
Secondary (>0 parasites per µL) 12 104/291 (36%) 75% (68–81) 75% (67–81)
Group 3 (control group)
Primary (>5000 parasites per µL) 6 105/147 (71%) NA NA
Primary (>5000 parasites per µL) 12 106/147 (72%) NA NA
Secondary (>0 parasites per µL) 6 118/147 (80%) NA NA
Secondary (>0 parasites per µL) 12 120/147 (82%) NA NA
Data are n/N (%) or % (95% CI), unless stated otherwise. Group 1 received 5 µg R21/25 µg Matrix-M, group 2 received 
5 µg R21/50 µg Matrix-M, and group 3 received Rabivax-S. Primary analysis was based on a modified intention-to-treat 
population. Primary case definition of clinical malaria is presence of axillary temperature of 37·5°C or higher and 
Plasmodium falciparum parasite density of more than 5000 asexual forms per µL. Secondary case definition of clinical 
malaria is presence of axillary temperature of 37·5°C or higher or history of fever within the last 24 h, or both, and 
P falciparum parasite density of more than 0. The Cox proportional hazards model was used to calculate hazard ratio. 
Vaccine efficacy was calculated by 1 minus the hazard ratio and expressed as a percentage. NA=not applicable. 
*Cox proportional hazards model, adjusted for sex, age category (5–9 months, 10–12 months, and >12 months) and 
adequate insecticide treated net use. All p values comparing vaccination groups to the control group for efficacy were 
less than 0·0001.
Table 1: Time to first episode of malaria meeting case definitions of clinical malaria episode, from 14 days 
to 6 and 12 months following third vaccination
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group 1 (table 2; appendix pp 7–8). No participants 
experienced febrile convulsions.
Unsolicited adverse events were collected for 28 days 
after each vaccination and were categorised according to 
the Medical Dictionary for Regulatory Activities preferred 
terms. 811 terms were assigned after three vaccinations, 
and there were no significant differences in number of 
events per group (appendix pp 7–9). Laboratory safety 
tests did not reveal any significant difference in the 
frequency of out-of-range values between the three 
treatment groups. Anaemia and leukocytosis were noted 
across the groups, but these events were assessed by 
masked study clinicians as not related to vaccinations. 
The only episodes of severe anaemia that occurred were 
during acute illness reported as serious adverse events 
and none were deemed related to vaccination (appendix 
p 3).
At baseline, no participant had detectable NANP IgG 
antibody levels. In group 1, titres reached a geometric 
mean of 6133 (95% CI 5161–7289) at 28 days after the 
third vaccination—about three times the level observed 
in vaccinated adults in the UK.17 In group 2, who received 
the higher dose of adjuvant, the level was significantly 
higher at 11 438 (9985–13 102; p<0·0001). These titres 
dropped over the following 12 months, but in both 
groups 1 and 2, 28 days after the fourth vaccination, 
antibodies were boosted to levels similar to those after 
the third vaccination (figure 3).
The antibody levels 28 days after the third vaccination 
were assessed for correlation with vaccine efficacy. After 
dividing antibody response levels to NANP of the 
combined group 1 and 2 participants into tertiles—an 
approach used successfully to identify an immune 
correlate of vaccine efficacy for RTS,S/AS012—there was 
a significantly reduced risk of malaria over 6 months 
for participants in the upper tertile compared with 
participants in the lower tertile (HR 0·34, 95% CI 
0·19–0·63; p<0·0001), and for participants in the upper 
Group 1 Group 2 Group 3
Local adverse event
Pain
1 6 (4%) 9 (6%) 3 (2%)
2 3 (2%) 3 (2%) 0 (0%)
3 0 (0%) 0 (0%) 0 (0%)
4 4 (3%) 0 (0%) 0 (0%)
Redness
1 2 (1%) 1 (1%) 0 (0%)
2 10 (7%) 14 (10%) 2 (1%)
3 2 (2%) 2 (1%) 1 (1%)
4 3 (2%) 0 (0%) 0 (0%)
Swelling
1 3 (2%) 5 (3%) 2 (1%)
2 14 (9%) 23 (16%) 10 (7%)
3 8 (6%) 11 (8%) 4 (3%)
4 3 (2%) 0 (0%) 0 (0%)
Systemic adverse event
Fever
1 14 (9%) 28 (19%) 13 (9%)
2 18 (12%) 44 (30%) 7 (5%)
3 18 (12%) 29 (20%) 16 (11%)
4 19 (14%) 34 (25%) 8 (6%)
Irritability
1 2 (1%) 5 (3%) 0 (0%)
2 0 (0%) 4 (3%) 0 (0%)
3 0 (0%) 0 (0%) 1 (1%)
4 1 (1%) 1 (1%) 1 (1%)
Drowsiness
1 0 (0%) 3 (2%) 1 (1%)
2 2 (1%) 6 (4%) 2 (1%)
3 0 (0%) 0 (0%) 0 (0%)
4 0 (0%) 2 (1%) 0 (0%)
Loss of appetite
1 1 (1%) 2 (1%) 1 (1%)
2 0 (0%) 3 (2%) 1 (1%)
3 0 (0%) 0 (0%) 0 (0%)
4 0 (0%) 1 (1%) 1 (1%)
Data are n or n (%). Group 1 received 5 µg R21/25 µg Matrix-M, group 2 received 
5 µg R21/50 µg Matrix-M, and group 3, the control group, received Rabivax-S. 
All solicited local and systemic adverse events were collected for 7 days after each 
vaccination. 150 participants in each group received the first dose of the 
vaccination. 149 participants in group 1, 147 participants in group 2 and 
149 participants in group 3 received a second dose. 146 participants in group 1, 
147 participants in group 2, and 149 participants in group 3 received a third 
dose. 132 participants in group 1, 138 participants in group 2, and 140 participants 
in group 3 received a fourth dose. Fever was defined as a temperature of 37·5°C or 
above. One participant in group 1 and one participant in group 2 had a severe 
fever (>39°C) after the third dose; all other adverse events were graded as mild or 
moderate. The grading of adverse events is given in the appendix (pp 13–91).
Table 2: Incidence of adverse events across all the groups by number of 
doses
Figure 3: Antibody responses to R21/MM
(A) Geometric mean antibody titres (95% CI). Anti-NANP antibodies were measured by ELISA at baseline; 28 days 
after first vaccination; 28 days, 6 months, and 1 year after the third vaccination; and 28 days after the booster 
(fourth) dose administered 1 year after the third dose. Group 1 received 5 µg R21/25 µg MM, group 2 received 5 µg 
R21/50 µg MM, and group 3, the control group, received Rabivax-S. MM=Matrix-M. NANP=Asn-Ala-Asn-Pro.
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tertile compared with participants in the middle tertile 
(0·46, 0·25–0·86; p<0·015).
Discussion
We report malaria vaccine efficacy that reaches the 
WHO-specified efficacy goal of 75% or more20 in the 
target population of African children, over 12 months of 
follow-up. Efficacy of 77% was observed in the children 
who received R21 plus the higher dose of MM adjuvant, 
and it was associated with an 86% increase in antibody 
titres to the CSP repeat, NANP, compared with the lower 
adjuvant dose after the third vaccination (figure 3). This 
efficacy has been studied in an area of highly seasonal 
malaria transmission.
R21/MM vaccinations were given before and during 
the start of the malaria season. It remains unclear 
whether, and by how much, vaccine efficacy might be 
increased by this approach in seasonal areas, but this is 
being studied with RTS,S/AS01 in Mali and Burkina Faso 
(NCT03143218).21 It is possible that vaccine efficacy might 
be further improved if administered earlier, so the 
primary series of vaccinations (all three doses) are 
completed some weeks before the season.
Despite the policy recommendation of four monthly 
courses of seasonal malaria chemoprevention in Burkina 
Faso,22 we found that most participants did not receive all 
doses from national programme administration during 
the malaria season. This study did not aim to ensure 
seasonal malaria chemoprevention delivery as per the 
national policy recommendation, but rather to document 
actual uptake and allow vaccine efficacy to be measured 
in this real-world context. A 2020 study concluded that 
malaria burden was still high in Burkina Faso, despite 
the introduction of seasonal malaria chemoprevention 
and a fifth monthly course would be of value.23 We are 
unaware of evidence that different levels of seasonal 
malaria chemoprevention use might alter vaccine 
efficacy, and adjusting for seasonal malaria chemo-
prevention use here did not alter vaccine efficacy 
estimates (data not shown).
MM24 has been administered as an adjuvant to tens of 
thousands of adults in vaccine trials for multiple diseases, 
including influenza and COVID-19,25,26 but this is the 
first report on its use in children. The vaccine was well 
tolerated at both adjuvant doses. Humoral immuno-
genicity after three doses was good, antibody titres were 
two-times higher in group 2 compared with group 1 
with the lower adjuvant dose. Levels were reboosted to 
comparable titres with a fourth dose at 12 months after 
the primary series of vaccinations.
R21 provides a high density of CSP epitopes on the 
particle surface, aiming to induce a high magnitude, and 
potentially better avidity, of antibodies to the central 
repeat of the CSP, by reducing antigenic compe tition 
with HBsAg sequences.10 HBsAg response rates have 
been very low in preclinical and UK phase 1/2 trials 
evaluating R21/MM, which have also shown high sterile 
efficacy rates of 63–78% using various vaccination 
regimens in controlled human malaria infection trials. 
This high efficacy in adults was observed with a low-dose 
R21 regimen of 10 µg.13,14
The most advanced malaria vaccine candidate, 
RTS,S/AS01, has progressed to pilot implementation 
trials8 after a large phase 3 trial showed efficacy of 36% 
(95% CI 32–41) over a median follow-up of 48 months,2 
but with 56% efficacy (97·5% CI 51–60) in children aged 
5–17 months in the first year.27 Possible safety signals 
are being assessed further in current implementation 
studies.7 The phase 3 RTS,S/AS01 trials administered 
vaccines all year round, but with R21/MM there was 
planned seasonal vaccine administration, which might 
contribute to the higher observed efficacy.
Our trial site, Nanoro, Burkina Faso, was one of 11 sites 
to do the RTS,S/AS01 phase 3 trial. Efficacy with R21 and 
the higher adjuvant MM dose, administered largely 
before the malaria season, was 77% (95% CI 67–84), 
compared with 44% (37–50) reported for RTS,S/AS01 at 
this site, without planned or implemented seasonal 
administration, over 12 months of follow-up.19 This 
efficacy was achieved with use of 5 µg doses of R21 
compared with 25 µg of RTS,S.
The most common local and systemic adverse events 
with RTS,S/AS01 across the phase 3 trial were pain at 
the injection site, after 12% (95% CI 11·4–13·4) of the 
primary series doses, and fever after 31% (30–33) of the 
primary series doses.27 These events appeared to be less 
frequent with R21/MM in this trial (table 2), 2% (group 1) 
and 3% (group 2) for pain and 12% (group 1) and 
23% (group 2) for fever, consistent with safety datasets 
from R21/MM phase 1/2a trials.13,15
We also found that antibodies to the central repeat of 
the CSP correlate strongly with protection, and the 
antibody titres in group 2 with the higher adjuvant dose 
were about six-times higher than in adults vaccinated in 
the UK,17 most of whom were protected in controlled 
human malaria infection trials.14 Levels of immuno-
genicity in adults vaccinated in Europe receiving 
RTS,S/AS0118,28 and R21/MM17 appear similar. These 
levels of immunogenicity increase four times when 
RTS,S/AS01 is administered to African children,2 and 
six times for R21/MM in group 2 of this trial.
A surprising finding of the kinetics of antibody 
response and efficacy with RTS,S/AS01 was that antibody 
immunogenicity after a fourth booster dose peaked at 
only about half the level observed after the third 
vaccination, and efficacy waned considerably over time.2 
This reduced reboosting of antibody levels might 
contribute to the increased incidence of malaria in the 
vaccinated children compared with controls observed in 
extended follow-up (years 4 to 7 after primary vacci-
nations) in the phase 2b and 3 RTS,S/AS01 trials.29,30 After 
a fourth dose of R21/MM, antibody titres are comparable 
to those measured after the third dose, suggesting that 
efficacy with this newer vaccine candidate could be better 
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maintained, at least through a second year of follow-up; 
this is currently being assessed.
This study has some limitations, including the short 
period of follow-up, although we have now extended 
the follow-up of this phase 2 trial. The age range of 
participants was limited to 5–17 months and a wider age 
range will be investigated in the future. There is also a 
need to evaluate larger numbers of participants to assess 
more fully the safety of a relatively new adjuvant 
formulation and document efficacy at sites with more 
perennial malaria transmission using non-seasonal 
vaccine administration.
An important advantage of R21/MM relates to its 
potential for large-scale manufacturing, which will be 
critical for the supply of hundreds of millions of doses 
of vaccine required annually for each birth cohort of 
children in malaria endemic regions of Africa. The R21 
paediatric dose is just 5 µg.31 The saponin adjuvant, 
MM, lacks the monophosphoryl lipid A adjuvant 
component,24 which is found in other adjuvants2 and is 
less complex to manufacture, and this enables large-
scale and low-cost supply of R21/MM. These factors 
con tribute to the future potential of R21/MM as a 
vaccine in countries where malaria is a major public 
health concern.
Follow-up of this phase 2 trial is currently continuing 
for a second malaria season, after a booster dose in 
June, 2020, to determine the durability of this high 
vaccine efficacy. A phase 3 trial across five African sites of 
differing malaria transmission and seasonality is 
underway, with the aim of licensure of a safe, low-cost, 
high efficacy vaccine, which can substantially reduce the 
malaria disease burden.
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